New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
08:26 EDTPPHMPeregrine updates progress in IST Phase I/II trial of bavituximab with sorafenib
Peregrine Pharmaceuticals announced the presentation of an update to the ongoing Investigator-Sponsored Trial, or IST, of its immunotherapy bavituximab in combination with the chemotherapy sorafenib in patients with advanced hepatocellular carcinoma, or HCC, or liver cancer. In a presentation titled: "Combination of Bavituximab and Sorafenib Inhibits HCC Growth: Results of Preclinical Data and a Phase I Study" Dr. Adam Yopp, Assistant Professor of Surgery at the University of Texas Southwestern Medical Center, Dallas, Texas provided an overview of the preclinical data and the ongoing Phase I/II trial. "The Phase II portion of this trial is ongoing with 34 of the 38 intended patients currently enrolled, 10 of which are currently on treatment with the longest one on treatment for 18 months," said Dr. Yopp. "This open-labeled trial is almost complete and while the results are preliminary, they are promising. I am excited about this potential combination given the new understandings about bavituximab's mechanism and I look forward to sharing the full set of data from this Phase II trial later this year." The Phase II portion of this trial is a single-center, single-arm, non-randomized, open-label trial with the primary endpoint of radiologic time to progression with imaging occurring at 6 week intervals. Secondary endpoints of the trial include overall survival, progression free survival, safety and response rates. The trial is scheduled to enroll 38 patients with advanced liver cancer. In addition, in order to leverage recent understandings surrounding the immune-stimulatory mechanism of action of bavituximab, several additional components have been installed into this portion of the trial. These include plasma and serum collection and tissue biopsies for evaluating changes in immune response following bavituximab treatment. Specifically, to assess whether combination therapy reactivates tumor immunity by changing the tumor microenvironment from immunosuppressive to immunoreactive, changing the tumor infiltrating cell composition or inducing T cell response to tumor antigens.
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
09:16 EDTPPHMOn The Fly: Pre-market Movers
Subscribe for More Information
December 10, 2014
16:07 EDTPPHMPeregrine provides update on product development activities
Subscribe for More Information
16:06 EDTPPHMPeregrine reports Q2 EPS (7c), consensus (7c)
Subscribe for More Information
15:25 EDTPPHMNotable companies reporting after market close
Subscribe for More Information
08:18 EDTPPHMAvid Bioservices expands cGMP manufacturing capacity
Avid Bioservices, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries. The new production facility will more than double Avid Bioservices' current manufacturing capacity in a state-of-the-art facility design. This facility will employ an innovative and flexible modular clean room design and the latest in single-use technologies that provide expanded capacity to meet the growing needs of Avid's existing and future clients. The capacity expansion will take place within an existing 40,000 square foot warehouse located adjacent to the company's current campus. The new cGMP facility will accommodate multiple single use bioreactors of up to 2,000 liters, downstream processing suites, and dedicated support utilities that will allow for the production of a variety of biological products.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use